Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

BACKGROUND: Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100) or atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg, have not been compared as initial antiretroviral treatment. To address this data gap, we conducted an open-label, multicenter 4...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Smith, Kimberly Y, Weinberg, Winkler G, DeJesus, Edwin, Fischl, Margaret A, Liao, Qiming, Ross, Lisa L, Pakes, Gary E, Pappa, Keith A, Lancaster, C Tracey
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2008
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2365957/
https://ncbi.nlm.nih.gov/pubmed/18373851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-6405-5-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars